Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?

Simply Wall St.07-14

Axsome Therapeutics recently dosed the first patient in FOCUS-2, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating solriamfetol in approximately 468 children aged 6 to under 12 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651910760?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-07-14 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651910760","market":"us","top_or_hot":-1,"title":"Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?","media":"Simply Wall St.","content":"<div>\n<p>Axsome Therapeutics recently dosed the first patient in FOCUS-2, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating solriamfetol in approximately 468 children aged 6 to under 12 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-14 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Axsome Therapeutics recently dosed the first patient in FOCUS-2, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating solriamfetol in approximately 468 children aged 6 to under 12 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with","article_id":"2651910760","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2651910760","pubTimestamp":1784039193,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Axsome Therapeutics recently dosed the first patient in FOCUS-2, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating solriamfetol in approximately 468 children aged 6 to under 12 with ADHD, measuring change in ADHD-RS-5 total score over 6 weeks.\nThis pediatric Phase 3 start, alongside an ongoing adolescent Phase 3 program, underscores Axsome’s push to broaden solriamfetol’s role across multiple CNS indications and age groups.\nWe’ll now examine how advancing solriamfetol...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CNS":"科恩-斯蒂尔斯金融","BK4135":"资产管理与托管银行","ABVC":"ABVC BioPharma, Inc.","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","AXSM":"Axsome Therapeutics, Inc.","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","BK4139":"生物科技"},"translate_title":"Axsome Therapeutics (AXSM) 是否正在通过儿科 Solriamfetol 试验扩展重新构建其中枢神经系统战略？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVC":0.61,"AXSM":1.5,"PTH":0.6,"CNS":1.5},"content_text":"Axsome Therapeutics recently dosed the first patient in FOCUS-2, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating solriamfetol in approximately 468 children aged 6 to under 12 with ADHD, measuring change in ADHD-RS-5 total score over 6 weeks. This pediatric Phase 3 start, alongside an ongoing adolescent Phase 3 program, underscores Axsome’s push to broaden solriamfetol’s role across multiple CNS indications and age groups. We’ll now examine how advancing solriamfetol into Phase 3 pediatric ADHD trials may influence Axsome’s CNS-focused investment narrative and risk profile. Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementAxsome Therapeutics Investment Narrative RecapTo own Axsome, you generally need to believe that its CNS portfolio can grow enough to offset current losses and heavy dependence on Auvelity and Sunosi. The new pediatric FOCUS-2 trial for solriamfetol supports that broader CNS story, but it does not materially change the near term focus on Auvelity execution and cash burn risk as the main catalysts and pressure points. Among recent announcements, the start of the FOCUS-3 Phase 3 trial of solriamfetol in adolescents with ADHD is most closely tied to this news. Together with FOCUS-2, it highlights Axsome’s effort to build a multi age ADHD franchise around solriamfetol, adding to the list of late stage programs that could eventually diversify revenue, but also contribute to sustained R&D and SG&A intensity in the coming years. Yet investors should also weigh how rising gross to net discounts across Auvelity, Sunosi and Symbravo could pressure realized revenue and margins if payer dynamics worsen... Read the full narrative on Axsome Therapeutics (it's free!)Axsome Therapeutics’ narrative projects $2.5 billion revenue and $981.8 million earnings by 2029.Uncover how Axsome Therapeutics' forecasts yield a $276.47 fair value, a 21% upside to its current price.Exploring Other PerspectivesAXSM 1-Year Stock Price Chart While consensus assumes Axsome can reach about US$1.5 billion revenue and US$433.1 million earnings by 2029, the lowest analysts highlight how heavy AUVELITY dependence and broad Phase 3 spending, even after this new ADHD trial news, could still leave you with a much more cautious view on the path to profits.Explore 7 other fair value estimates on Axsome Therapeutics - why the stock might be worth over 3x more than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Axsome Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.Looking For Alternative Opportunities?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Uncover the next big thing with 20 elite penny stocks that balance risk and reward.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651910760","isCrawlerRequest":true}